Sly Syndrome Terminated Phase 2 Trials for Alemtuzumab (DB00087)

IndicationStatusPhase
DBCOND0040268 (Sly Syndrome)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00668564Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of MetabolismTreatment